Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Michal Hayun"'
Autor:
Yuval Shaked, Ron N. Apte, Elena Voronov, Marina Bersudsky, Noa Lavi, Michal Hayun, Shimrit Avraham, Michael Timaner, Yael Cohen, Irit Avivi, Noga Barak, Anat Reiner-Benaim, Ksenia Magidey, Ofrat Beyar-Katz
Multiple myeloma (MM) is a plasma cell neoplasia commonly treated with proteasome inhibitors such as bortezomib. Although bortezomib has demonstrated enhanced survival benefit, some patients relapse and subsequently develop resistance to such therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18c6c7c64a0ed62df3c722c385ba35f2
https://doi.org/10.1158/1541-7786.c.6541101
https://doi.org/10.1158/1541-7786.c.6541101
Autor:
Yuval Shaked, Ron N. Apte, Elena Voronov, Marina Bersudsky, Noa Lavi, Michal Hayun, Shimrit Avraham, Michael Timaner, Yael Cohen, Irit Avivi, Noga Barak, Anat Reiner-Benaim, Ksenia Magidey, Ofrat Beyar-Katz
Figure S1. Bone marrow-derived macrophages enrich MM TICs. Figure S2. IL-1β promotes MM-TIC enrichment. Figure S3. Reduced survival in MM patients with high levels of M1 pro-inflammatory macrophages and TICs. Table S1: Patient characteristics and tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46aa6d8376fed290c5d6a754f5bf3903
https://doi.org/10.1158/1541-7786.22515483
https://doi.org/10.1158/1541-7786.22515483
Autor:
Shimrit Avraham, Marina Bersudsky, Irit Avivi, Yael Cohen, Michal Hayun, Noga Barak, Michael Timaner, Noa Lavi, Elena Voronov, Ron N. Apte, Yuval Shaked, Ofrat Beyar-Katz, Ksenia Magidey, Anat Reiner-Benaim
Publikováno v:
Molecular Cancer Research
Multiple myeloma (MM) is a plasma cell neoplasia commonly treated with proteasome inhibitors such as bortezomib. Although bortezomib has demonstrated enhanced survival benefit, some patients relapse and subsequently develop resistance to such therapy
Autor:
Tehila Azoulay, Ilana Slouzky, Michal Karmona, Margarita Filatov, Michal Hayun, Yishai Ofran, Galit Sarig, Shimrit Ringelstein-Harlev
Publikováno v:
Cancer immunology, immunotherapy : CII.
While natural killer (NK) cells are essential players in detection and elimination of malignant cells, these surveillance properties can be compromised by cancer cells. Since NK cell education primarily occurs in the bone marrow and lymphoid tissue,
Publikováno v:
Journal of Cellular and Molecular Medicine
Autor:
Hagit N. Baris, Yishai Ofran, Chen Itzkovich, Igal Louria-Hayon, Nivin Moustafa-Hawash, Shimrit Ringelstein-Harlev, Michal Hayun, Margarita Filatova, Dvora Sahar, Maria Zaatra, Dina Rosenberg
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Selection of resistant clones following intensive chemotherapy is a common obstacle for cure in many cancers, particularly in acute myeloid leukemia (AML). In AML, clone-specific sensitivity to chemotherapy varies even within the same patient. Multip
Autor:
Yishai Ofran, Michal Hayun, Ayelet Alpert, Tyler J. Curiel, Elina Starosvetsky, Shai S. Shen-Orr, Ornit Nahman
Publikováno v:
Cell Syst
Single-cell technologies allow characterization of cancer samples as continuous developmental trajectories. Yet, the obtained temporal resolution cannot be leveraged for a comparative analysis due to the large phenotypic heterogeneity existing betwee
Autor:
Michal Hayun, Avraham Frisch, Yishai Ofran, Tsila Zuckerman, Israel Henig, Dana Yehudai-Ofir, Ofrat Beyar-Katz, Ilana Slouzkey, Shimrit Ringelstein-Harlev
Publikováno v:
Leukemia. 34:293-295
Autor:
Ron Hoffman, Ilana Hellmann, Tsila Zuckerman, Israel Henig, Revital Saban, Ariella Tvito, Chezi Ganzel, Ariela Arad, Michal Hayun, Jacob M. Rowe, Sharon Gino-Moor, Ronit Leiba, Noa Lavi, Shimrit Ringelstein, Netanel A. Horowitz, Yishai Ofran, Moshe E. Gatt, Avraham Frisch, Ron Ram, Shlomo Bulvik
Publikováno v:
American journal of hematologyREFERENCES. 95(1)
Autor:
Ilana Hellmann, Ariela Arad, Yishai Ofran, Netanel A. Horowitz, Tsila Zuckerman, Israel Henig, Michal Hayun, Ronit Leiba, Noa Lavi, Revital Saban, Shimrit Ringelstein, Shlomo Bulvik, Ron Hoffman, Chezi Ganzel, Jacob M. Rowe, Sharon Gino-Moor, Ron Ram, Moshe E. Gatt
Publikováno v:
American Journal of Hematology. 90:1159-1164
Evaluation of early response during induction therapy for acute myeloid leukemia (AML) is used for prognostication and re-induction strategy, yet the optimal evaluation time point is unknown. Clearance of bone marrow (BM) blasts by day 14 of therapy